Why the Neurology Clinical Trials Market Is Set to Nearly Double by 2034 — and What It Means for Pharma and CRO Leaders

Alzheimer's, Parkinson's, and stroke are affecting a growing share of an aging global population, and the search for effective treatments is intensifying at a pace few other therapeutic areas can match. According to Polaris Market Research, the global Neurology Clinical Trials market was valued at USD 5.60 billion in 2024 and is projected to reach USD 10.59 billion by 2034, growing at a CAGR of 6.6% from 2025 to 2034, as pharmaceutical companies and research institutions race to develop new and more effective therapies.

The Shift: What's Actually Changing in Neurology Clinical Trials

Trial design itself is evolving. Sponsors are leaning on AI to interpret dense EEG, neuroimaging, and behavioral datasets, identify eligible patients from real-world records, and speed up recruitment for historically hard-to-fill studies. At the same time, decentralized trial models, wearable cognitive testing, and digital biomarkers are lowering the barrier for patients with mobility or travel constraints to participate, weaving new market trends into an already complex research landscape.

Regulators are adapting too. Agencies such as the FDA and EMA are providing clearer guidance on digital therapeutics and real-world data, which is giving sponsors more confidence to build trials around continuous, remote data collection rather than periodic in-clinic visits — a shift that is particularly valuable for progressive conditions like Alzheimer's, where long-term monitoring matters as much as the initial intervention.

Neurology Clinical Trials Market by the Numbers

• 2024 Market Size: USD 5.60 Billion
• 2025 Market Size: USD 5.96 Billion
• 2034 Projected Market Size: USD 10.59 Billion
• CAGR (2025–2034): 6.6%
• Largest Region in 2024: North America

Growth Drivers, Key Players and Market Segments to Watch

Growth is being driven by the rising global burden of neurological disease and expanding government research funding — including NIH-backed initiatives through the National Institute of Neurological Disorders and Stroke — with key players including IQVIA, ICON plc, Syneos Health, and Laboratory Corporation of America Holdings, alongside pharmaceutical sponsors such as Pfizer and Biogen, shaping the competitive landscape across segments such as By Phase (Phase I–IV), By Indication (Alzheimer's, Parkinson's, ALS), and By Value Chain (in-house, CROs, investigator sites).

By phase, Phase III trials held the largest share in 2024 given their scale and cost as the final step before regulatory submission, while Phase I studies are set to grow fastest as more gene- and stem-cell-therapy candidates enter early development. By indication, Alzheimer's disease remains the single largest category given its sheer patient volume, but ALS is forecast to be the fastest-growing indication as new research methods target rare, currently untreatable conditions.

North America Leads Today, but Asia Pacific Is Catching Up Fast

North America currently commands the largest share of the market, supported by a dense concentration of pharmaceutical and biotech R&D, deep research budgets, and a well-established, if strict, regulatory pathway. Asia Pacific is closing the gap, however, offering sponsors access to large, diverse patient populations, lower operational costs, and increasingly supportive regulatory environments — a combination that is steadily pulling trial activity, along with Eastern Europe and Latin America, toward these emerging regions.

👉 Want the full data behind this shift? Get a Free Sample Report → https://www.polarismarketresearch.com/industry-analysis/neurology-clinical-trials-market 

What This Means for Teams Evaluating Trial Sites and CRO Partners

For sponsors and research teams evaluating trial sites and CRO partners, the underlying report breaks down company positioning, segment-level forecasts, and regional opportunity through 2034 — useful context for any partnership, site-selection, or investment conversation happening right now, especially as U.S. tariff-driven cost pressure on lab instruments, imaging technology, and biologics pushes some sponsors to diversify where trials are run and consider nearshoring or local sourcing strategies to protect timelines.

The Road Ahead

Neurology Clinical Trials Market Expect continued consolidation as pharmaceutical companies acquire biotech firms with strong neurology pipelines, alongside deeper CRO investment in wearables, remote assessments, and advanced neuroimaging to manage increasingly complex trial protocols. Phase III studies will likely keep the largest share of spend, even as observational designs post the fastest growth in study design as demand for real-world evidence continues to climb.

Strengthening specialized neurology site networks, expanding eConsent and virtual cognitive testing, and forming local CRO partnerships in emerging regions will likely define the next few years of competitive activity, as sponsors try to balance trial speed against rising costs and increasingly complex regulatory requirements.

More Trending Latest Reports By Polaris Market Research:

medical-devices-market

natural-disaster-management-market

petrochemicals-market

autonomous-mobile-robot-market

intraocular-lens-market

us-industrial-fans-market

benchmarking-performance-top-5-companies-in-air-purifiers